|
|
 |
|
Viewing report
|
|
|
|
U.S. Emerging Osteoporosis Therapeutics Markets
Frost & Sullivan, April 2002
Lack of Disease Awareness Restrains Industry Growth
Many doctors and potential patients remain unaware of the signs of
osteoporosis, which is characterized by low bone mass and structural
deterioration of bone tissue. Consequently, only one-third of the 10 million
Americans suffering from this progressive disease are diagnosed and treated
for their condition. As long as awareness remains low, markets for
therapeutics will fall short of their revenue potential.
This Frost & Sullivan study analyzes the U.S. markets for osteoporosis
therapeutics, including markets for estrogen replacement therapy (ERT),
biphosphonates, selective estrogen receptor modulators, calcitonin, and other
emerging therapies. By examining market drivers and restraints and by
presenting expert revenue forecasts for each segment, this study gives its
readers key insights into the future of this field.
Product Differentiation Is Crucial to Introducing New Therapies
Drug companies with novel drugs in the pipeline for the prevention and
treatment of osteoporosis are challenged to differentiate their new products
from existing therapies, says the study’s author. Because estrogen therapies,
for example, are viewed as clinically similar, doctors tend to pass over new
products for drugs that they regularly prescribe.
Until market participants can successfully differentiate their products from
those of their competitors, they will not succeed in unseating traditional
market leaders, states the analyst. This study, which highlights industry
challenges and provides extensive strategic recommendations, can help your
firm increase its market presence.
Bone Formation Drugs Promise New Opportunities
Existing anti-resorptive therapies are unable to replace lost bone or rebuild
new bone mass. As a result, patients with severe osteoporosis are at a very
high risk of developing fractures. Drug companies have responded to this
unmet medical need by developing bone formation drugs, such as the
parathyroid hormone, which have the potential to reverse bone loss and
rebuild bone density in patients with advanced osteoporosis.
The development of bone formation drugs will revolutionize the osteoporosis
market. Demand will be high among patients who have failed existing therapies,
says the author. This study tracks the progress of new therapies to enable your
company to optimize its research and development efforts.
Additional Information
Market Participants
Amgen, Inc.
Aventis Pharmaceuticals, Inc.
Berlex Laboratories, Inc.
Bone Care International, Inc.
Bristol-Myers Squibb Co.
Discovery Labs, Inc.
Eli Lilly & Company
Emisphere Technologies, Inc.
GlaxoSmithKline Plc
Inhale Therapeutic Systems, Inc.
Insmed, Inc.
Ligand Pharmaceuticals, Inc.
Merck & Co., Inc.
Mission Pharmacal Co.
Mylan Laboratories, Inc.
Nobex Corp.
Novartis Pharmaceutical Corp.
Novavax, Inc.
Noven Pharmaceuticals, Inc.
NPS Pharmaceuticals, Inc.
Organon, Inc.
Pfizer, Inc.
Pharmacia Corporation
Procter & Gamble Pharmaceuticals, Inc.
Qualitest Pharmaceuticals, Inc.
Roche US Pharmaceuticals
Solvay Pharmaceuticals, Inc.
TheraTechnologies, Inc.
Unigene Laboratories, Inc.
Watson Pharmaceuticals, Inc.
Women First HealthCare, Inc.
Wyeth-Ayrest Laboratories
Aerospace
Auto ID
Biotech
Chemicals
Conferencing
Consumer
e-Business
Environment
Food
Healthcare
Internet Security
IT
Latin America
Medical Devices
Motors
Pharmaceuticals
Power
Sensors
Smart Cards
Technical Insights
Telecom Services
Transportation
Water
Wireless
Customers who bought this item also bought
Osteoporosis Therapeutics - A Global Market Perspective
Osteoporosis Therapeutics - A Global Market Perspective
US Osteoporosis Market
Osteoporosis Therapeutics - Global Strategic Business Report
U.S. Osteoporosis Therapeutics Markets
Osteoporosis - Novel Agents to Battle for Payer Acceptance
The 2009 Report on Estrogen Hormones and Synthetic Substitute Pharmaceuticals: World Market Segmentation by City
Therapeutic and Pharmaceutical Opportunities for Osteoporosis and Atherosclerosis
Stakeholder Insight: Osteoporosis - Generic Alendronate Further Establishes Oral Bisphosphonates as Gold Standard
The 2009-2014 World Outlook for Estrogen Hormones and Synthetic Substitute Pharmaceuticals
The 2009-2014 Outlook for Estrogen Hormones and Synthetic Substitute Pharmaceuticals in Greater China
The 2009-2014 Outlook for Estrogen Hormones and Synthetic Substitute Pharmaceuticals in Japan
|
|
|
|
